Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of Dasatinib plus CD19/CD22 Bispecific CAR-T for the
treatment of elderly Ph-positive lymphoblastic leukemia. Newly diagnosed Ph-positive patients
will be given Dasatinib plus VP chemotherapy for induction treatment,if a hematologic
complete remission was observed then a lymphocyte collection will be administrated to
patients. Then chemotherapy regimen of fludarabine and cyclophosphamide followed by a single
infusion of CD19/CD22 CAR+ T cells
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine